Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic
Publishing timestamp: 2023-10-13 12:49:23
Summary
Novo Nordisk has raised its outlook for full-year sales and operating profit due to high demand for its weight loss drug Wegovy and diabetes treatment Ozempic. The revised forecast reflects the frenzy for these weekly injections, which are sought after for their ability to help patients lose significant weight over time. Novo Nordisk expects strong sales growth and operating profit growth, making it Europe's most valuable company. The company's U.S.-listed shares rose about 1% and reached a new 52-week high.
Sentiment: POSITIVE
Tickers: NOVO.B-DK,
Keywords: business news, business, breaking news, biotechnology, novo nordisk a/s, earnings, united states, health care industry, pharmaceuticals, biotech and pharmaceuticals,
Source: https://www.cnbc.com/2023/10/13/novo-nordisk-hikes-outlook-on-soaring-demand-for-wegovy-ozempic.html